Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To show that maintenance therapy with Tislelizumab plus Anlotinib will prolong Progression
Free Survival in subjects with extensive stage disease small cell lung cancer who have
completed first line chemotherapy.